Core Insights - Innovent Biologics is showcasing preclinical data on multiple novel bispecific antibodies, tri-specific antibodies, and bispecific antibody-drug conjugates (ADCs) at the AACR Annual Meeting 2025, highlighting its advancements in oncology research [1][2] Research Highlights - IAR037, a novel CD40/PD-L1 bispecific antibody, shows potent anti-tumor efficacy in PD-1-resistant models and has a favorable safety profile in cynomolgus monkeys [3][4] - IBI3010, a FRα targeting biparatopic ADC, demonstrates superior cytotoxicity compared to existing treatments and is being developed for FRα-expressing tumors [5][6] - IBI3014, a TROP2xPD-L1 bispecific ADC, integrates tumor killing with immune checkpoint blockade, showing promising efficacy and safety in preclinical models [8][9] - IBI3022 targets Trop2 and B7H4, exhibiting improved efficacy and safety profiles for gynecologic cancers [10][11] - IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, shows potential as a new immuno-oncology therapy with strong immune activation [12][13] - IBI3019, a tri-specific antibody for colorectal cancer, demonstrates potent efficacy and an excellent safety profile in preclinical studies [16][17] - A novel PD1-IFNα fusion protein shows superior anti-tumor efficacy compared to PD1 mAb alone, potentially benefiting patients with ICB-refractory cancers [18][19][20] Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, having launched 15 products and with multiple assets in clinical trials [21]

Core Viewpoint - Innovent Biologics is set to present preclinical data on multiple novel bispecific antibodies and antibody-drug conjugates (ADCs) at the AACR Annual Meeting 2025, showcasing its advancements in oncology research and commitment to innovative therapies for major diseases [1][7]. Group 1: Preclinical Data Presentations - The company will present data on IAR037, a novel CD40/PD-L1 bispecific antibody targeting advanced solid tumors resistant to immune checkpoint inhibitors, on April 28, 2025 [2]. - IBI3010, a FRα targeting biparatopic ADC for FRα expressing tumors, will also be presented on April 28, 2025 [2]. - IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against colorectal cancer (CRC) in preclinical studies, with a presentation scheduled for April 29, 2025 [3]. Group 2: Innovative Therapeutics - IBI3026, an anti-PD-1/IL-12 fusion protein, shows potential as a new immuno-oncology therapy by activating T and NK cells in the tumor microenvironment, with a presentation on April 28, 2025 [3]. - IBI3014, a TROP2xPD-L1 bi-specific ADC, integrates ADC killing with checkpoint blockade and exhibits promising efficacy in preclinical models, scheduled for presentation on April 27, 2025 [4]. - A 2+1 format MUC16 targeting T cell engager has been shown to induce superior anti-tumor efficacy, with a presentation on April 28, 2025 [5]. Group 3: Collaborations and Market Position - Innovent has launched 15 products and has 3 new drug applications under regulatory review, along with 3 assets in Phase III trials and 16 molecules in early clinical stages, indicating a robust pipeline [8]. - The company partners with over 30 global healthcare companies, enhancing its research and development capabilities and market reach [8].